The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
APAC to see a reduction in imported surgical robotics
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Swiftmelt 1515-I meets performance requirements and secures skin attachment
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The company is one of the most profitable companies manufacturing speciality chemicals in India
Cipla and Ethris partner for the development of mRNA-based therapies
Subscribe To Our Newsletter & Stay Updated
